Olmesartan medoxomil-based therapy for the management of hypertension.

about

Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.

P2860

Q38466210-A943176B-564B-412A-937E-120A6C54B3C5

P2860

Olmesartan medoxomil-based therapy for the management of hypertension.

Item

http://www.wikidata.org/entity/Q38178325

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Olmesartan medoxomil-based therapy for the management of hypertension.

@en

type

Item

label

Olmesartan medoxomil-based therapy for the management of hypertension.

@en

prefLabel

Olmesartan medoxomil-based therapy for the management of hypertension.

@en

P1476

Olmesartan medoxomil-based therapy for the management of hypertension.

@en

P2093

Mark Greathouse

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Clinical studies of CS-866, the newest angiotensin II receptor antagonist.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

P304

593-604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.1.5.593

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24422732

http://www.w3.org/2001/XMLSchema#string

Olmesartan medoxomil-based therapy for the management of hypertension.

about

P2860

P2860

Olmesartan medoxomil-based therapy for the management of hypertension.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698